These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31876083)

  • 1. Change in 21-gene Recurrence Score result after exposure to neo-adjuvant endocrine therapy in patients with operable breast cancer.
    Hilal T; Mi L; Ertz-Archambault NM; Almquist DR; Anderson KS; Gray RJ; Pockaj BA; Northfelt DW
    Breast J; 2020 Jul; 26(7):1449-1451. PubMed ID: 31876083
    [No Abstract]   [Full Text] [Related]  

  • 2. Adherence to adjuvant endocrine therapy for breast cancer: importance in women with low income.
    Ursem CJ; Bosworth HB; Shelby RA; Hwang W; Anderson RT; Kimmick GG
    J Womens Health (Larchmt); 2015 May; 24(5):403-8. PubMed ID: 25884292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective.
    Dixon JM; Anderson TJ; Miller WR
    Eur J Cancer; 2002 Nov; 38(17):2214-21. PubMed ID: 12441257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
    Sparano JA; Gray RJ; Ravdin PM; Makower DF; Pritchard KI; Albain KS; Hayes DF; Geyer CE; Dees EC; Goetz MP; Olson JA; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Paik S; Wood WC; Keane MM; Gomez Moreno HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Berenberg JL; Abrams J; Sledge GW
    N Engl J Med; 2019 Jun; 380(25):2395-2405. PubMed ID: 31157962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neoadjuvant antihormonal treatment of women with breast cancer].
    Tuxen MK; Kamby C; Nielsen DL
    Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
    Buzdar AU;
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Future endocrine therapy of breast cancer].
    Ejlertsen B
    Ugeskr Laeger; 2007 Jan; 169(4):296. PubMed ID: 17274921
    [No Abstract]   [Full Text] [Related]  

  • 10. Neoadjuvant endocrine treatment in breast cancer: analysis of daily practice in large cancer center to facilitate decision making.
    Debled M; Auxepaules G; de Lara CT; Garbay D; Brouste V; Bussières E; Mauriac L; MacGrogan G
    Am J Surg; 2014 Nov; 208(5):756-763. PubMed ID: 24814311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
    Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adjuvant medical treatment for patients with locoregional recurrence of breast cancer].
    Farooq FC; Kamby C
    Ugeskr Laeger; 2016 Feb; 178(5):V08150648. PubMed ID: 26857300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer: new aspects of adjuvant hormonal therapy.
    Lohrisch C; Piccart M
    Ann Oncol; 2000; 11 Suppl 3():13-25. PubMed ID: 11079114
    [No Abstract]   [Full Text] [Related]  

  • 14. Tamoxifen versus toremifene in the adjuvant treatment of breast cancer.
    Holli K;
    Eur J Cancer; 2002 Nov; 38 Suppl 6():S37-8. PubMed ID: 12409068
    [No Abstract]   [Full Text] [Related]  

  • 15. Neo adjuvant Tamoxifen in post menopausal patients with operable breast cancer.
    Salmon RJ; Remvikos Y; Campana F; Languille O; Magdalenat H; Asselain B; Clough KB;
    Eur J Surg Oncol; 2003 Dec; 29(10):831-4. PubMed ID: 14624772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests.
    Saponaro M; Annunziata L; Turla A; Viganò I; De Laurentiis M; Giuliano M; Del Mastro L; Montemurro F; Puglisi F; De Angelis C; Buono G; Schettini F; Arpino G
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New developments in endocrine therapy: role of adjuvant therapy for early breast cancer.
    Grana G
    Cancer Nurs; 2003 Dec; 26(6 Suppl):4S-9S. PubMed ID: 15025406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting benefit of endocrine therapy for early breast cancer.
    Regan MM
    Breast; 2015 Nov; 24 Suppl 2(0 2):S129-31. PubMed ID: 26255197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.